These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 20578904

  • 1. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK.
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [Abstract] [Full Text] [Related]

  • 2. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians.
    Poduri A, Khullar M, Bahl A, Sharma YP, Talwar KK.
    DNA Cell Biol; 2009 Sep; 28(9):451-60. PubMed ID: 19558216
    [Abstract] [Full Text] [Related]

  • 3. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH.
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [Abstract] [Full Text] [Related]

  • 4. [Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
    Gao J, Cong HL, Mao YM, Liu Y, Zhang N, Chen Q, Liu T, Cui R.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):553-8. PubMed ID: 24078569
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Cerda A, Genvigir FD, Arazi SS, Hirata MH, Dorea EL, Bernik MM, Bertolami MC, Faludi AA, Hirata RD.
    Clin Chim Acta; 2010 May 02; 411(9-10):631-7. PubMed ID: 20064494
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.
    Gu GL, Xu XL, Yang QY, Zeng RL.
    Med Sci Monit; 2014 Dec 30; 20():2824-9. PubMed ID: 25547030
    [Abstract] [Full Text] [Related]

  • 15. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
    Andrén L, Andreasson A, Eggertsen R.
    Eur J Clin Pharmacol; 2007 Oct 30; 63(10):913-6. PubMed ID: 17701167
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF, Mishriki AA, Issac MS, Bakhoum SW.
    Mol Diagn Ther; 2013 Oct 30; 17(5):299-309. PubMed ID: 23677857
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.